Reference : Effects of reducing blood pressure on cardiovascular outcomes and mortality in patien...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/203700
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
English
Scheen, André mailto [Université de Liège > Département des sciences cliniques > Département des sciences cliniques >]
2016
Diabetes Research and Clinical Practice
121
204-214
Yes (verified by ORBi)
International
0168-8227
1872-8227
Ireland
[en] Blood pressure ; Diuretic ; Empagliflozin ; Hypertension ; SGLT2 inhibitor ; Type 2 diabetes
[en] Empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, has shown a remarkable reduction in cardiovascular and all-cause mortality in patients with type 2 diabetes (T2D) and antecedents of cardiovascular disease in the EMPA-REG OUTCOME trial. This effect has been attributed to a hemodynamic rather than a metabolic effect, partly due to the osmotic/diuretic effect of empagliflozin and to the reduction in arterial blood pressure. The present review will: (1) summarize the results of specific studies having tested the blood pressure lowering effects of SGLT2 inhibitors; (2) describe the results of meta-analyses of trials having evaluated the effects on mortality and cardiovascular outcomes of lowering blood pressure in patients with T2D, with a special focus on baseline and target blood pressures; (3) compare the cardiovascular outcome results in EMPA-REG OUTCOME versus other major trials with antihypertensive agents in patients with T2D; and (4) evaluate post-hoc analyses from EMPA-REG OUTCOME, especially subgroups of patients of special interest regarding the blood pressure lowering hypothesis. Although BP reduction associated to empagliflozin therapy may partly contribute to the benefits reported in EMPA-REG OUTCOME, other mechanisms most probably play a greater role in the overall CV protection and reduction in mortality observed in this trial.
http://hdl.handle.net/2268/203700
10.1016/j.diabres.2016.09.016
Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
2016 DCRP SGLT2 reducing BP.pdfAuthor preprint515.03 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.